Olema Pharmaceuticals Q3 2026 earnings

OLMA · 2026-11-10 07:05 BMO ET · 8-K on SEC · 10-Q on SEC

Net loss widened to $73.6 million as R&D spending accelerated for late-stage clinical trials and commercial preparation.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $77.5M (+69.0% YoY)
  • One-offs in the quarter Non-cash stock-based compensation: $7.7M (R&D), $4.4M (G&A); Other (loss) income: $128k
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge Excludes non-cash stock-based compensation from R&D and G&A; excludes other (loss) income.

KPIs

MetricActualPrior quarterPrior yearChange
Weighted average shares101.1M104.5M85.7M-3.3% QoQ, +18.0% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported; company is clinical-stage.
  • EPS story Net loss per share widened to $0.73 from $0.49 YoY, driven by higher operating expenses and share count.
  • One-off check Non-cash stock-based compensation increased to $12.1M total ($7.7M R&D, $4.4M G&A) from $5.3M YoY.

The good

  • Cash balance of $413.8M supports operations through 2027 catalysts.

The bad

  • Net loss widened $31.4M YoY due to increased clinical and commercial spending.
  • Cash balance declined $47.3M QoQ to $413.8M.

The ugly

  • none

Open questions

  • When will the company generate revenue?
  • What is the specific burn rate for the remaining cash balance?
Full release

Olema Pharmaceuticals (OLMA) earnings release, November 10, 2026

Olema Pharmaceuticals, Inc. (OLMA) · Form 8-K, Item 2.02 · Filed · SEC filing

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

• On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027

• Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136

• Appointed Jason O’Byrne, MBA, as Chief Financial Officer

• Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities

SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026.

“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “Turning to our pivotal Phase 3 OPERA-02 trial in first-line metastatic breast cancer, momentum continues to build. Enrollment is accelerating, investigator interest is strong, and patients with frontline disease continue to require better therapeutic options. We believe that palazestrant, in combination with ribociclib, is well positioned to become the new standard of care in this setting. With its dual mechanism of action as a complete estrogen receptor antagonist and selective estrogen receptor degrader, optimal pharmacokinetic properties, encouraging clinical profile demonstrated to date, and potential for use both as a monotherapy and in combination with other agents, we believe palazestrant is uniquely positioned to transform the metastatic breast cancer treatment paradigm.”

Bohen continued, “Beyond preparing for the potential approval and commercialization of palazestrant, we remain encouraged by the potential of OP-3136, our novel KAT6 inhibitor, as it advances through clinical development across multiple indications and treatment combinations. We were also pleased to welcome Jason O’Byrne as Chief Financial Officer this quarter. His extensive experience in corporate strategy, capital markets, and financial management and operations will be invaluable as we prepare for key catalysts in 2027 and continue our transformation into a fully integrated oncology company.”

Anticipated Upcoming Events

• Present preclinical data on selective degradation of KAT6A in estrogen receptor-positive breast cancer at the 38 th

EORTC-NCI-AACR Symposium 2026 on Molecular Targets and Cancer Therapeutics (ENA) in November.

• Present data from the Phase 1b/2 study of OP-3136 in combination with fulvestrant, the Phase 1b/2 study of palazestrant in combination with everolimus, and the Phase 1b study of palazestrant in combination with atirmociclib, all in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, at the 2026 San Antonio Breast Cancer Symposium (SABCS) in December.

• Initiate enrollment in the Phase 1b/2 study evaluating OP-3136 in combination with darolutamide in mCRPC in collaboration with Bayer in the fourth quarter of 2026.

• Report top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027.

Third Quarter 2026 Financial Results

Cash, cash equivalents, and marketable securities as of September 30, 2026, were $413.8 million.

Net loss for the quarter ended September 30, 2026 was $73.6 million, as compared to $42.2 million for the quarter ended September 30, 2025. The increase in net loss for the third quarter was primarily related to increased patient enrollment in our OPERA-01 Phase 3 clinical trial, strong patient enrollment in our OPERA-02 Phase 3 clinical trial, continued advancement of our Phase 1b/2 OP-3136 clinical program, research activities, increased manufacturing and clinical supply activities in support of advancing clinical programs and early preparations for the potential commercialization of palazestrant and higher personnel related costs.

GAAP research and development (R&D) expenses were $67.6 million for the quarter ended September 30, 2026, as compared to $40.0 million for the quarter ended September 30, 2025. The increase in R&D expenses was primarily related to increased spending on the continued enrollment of our pivotal Phase 3 OPERA-01 and OPERA-02 clinical trials for palazestrant, increased manufacturing and clinical supply activities supporting these programs, continued advancement of our Phase 1 OP-3136 clinical program, and higher personnel-related costs to support expanding development activities, including an increase in non-cash stock-based compensation expense of $5.1 million, mainly due to higher grant prices in 2026 and higher headcount.

Non-GAAP R&D expenses were $59.9 million for the quarter ended September 30, 2026, excluding $7.7 million non-cash stock-based compensation expense. Non-GAAP R&D expenses were $37.4 million for the quarter ended September 30, 2025, excluding $2.6 million non-cash stock-based compensation expense. A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.... (truncated)26, and an increase in professional fees of $1.0 million.

Non-GAAP G&A expenses were $5.5 million for the quarter ended September 30, 2026, excluding $4.4 million non-cash stock-based compensation expense. Non-GAAP G&A expenses were $4.3 million for the quarter ended September 30, 2025, excluding $1.7 million non-cash stock-based compensation expense. A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

About Palazestrant (OP-1250)

Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.

About OP-3136

OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study.

Non-GAAP Financial Information

The results presented in this press release include both GAAP information and non-GAAP information. As used in this release, non-GAAP R&D expense is defined by Olema as GAAP R&D expense excluding stock-based compensation expense, and non-GAAP G&A expense is defined by Olema as GAAP G&A expense excluding stock-based compensation expense. We use these non-GAAP financial measures to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except for share and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating expenses:
Research and development (1)67,59839,951174,615114,477
General and administrative (2)9,9275,92628,07514,137
Total operating expenses77,52545,877202,690128,614
Loss from operations-77,525-45,877-202,690-128,614
Other income:
Interest income4,0543,64813,33712,214
Other (loss) income-12812-53510
Total other income3,9263,66012,80212,224
Net loss-73,599-42,217-189,888-116,390
Net loss per share, basic and diluted-0.73-0.49-1.89-1.36
Weighted average shares used to compute net loss per share, basic and diluted (3)101,092,70685,732,221100,609,25885,553,078

Balance Sheet

September 30, — (In thousands)

September 30, – 2026December 31, – 2025
Cash, cash equivalents and marketable securities413,771505,437
Total assets441,070533,430
Total current liabilities69,23351,802
Total liabilities72,23354,871
Total stockholders’ equity368,837478,559
Total liabilities and stockholders’ equity441,070533,430

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (Amounts in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-189,888-116,390
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense315303
Non-cash lease expense899875
Non-cash interest income on marketable securities-3,367-5,135
Stock-based compensation expense, including employee stock purchase plan expense35,13313,320
Loss on sale of equipment98
Change in assets and liabilities:
Prepaid expenses and other current assets1,675-960
Other assets and long-term deposits-716-5,649
Accounts payable-8,044-1,175
Other current liabilities25,8397,353
Operating lease liabilities-939-931
Net cash used in operating activities-138,995-108,389
Cash flows from investing activities:
Purchase of equipment-1,121
Proceeds from sale of equipment50
Maturities of marketable securities260,995253,794
Purchases of marketable securities-168,953-247,370
Net cash provided by investing activities90,9716,424
Cash flows from financing activities:
Issuance of shares under at-the-market offering, net of issuance costs of $4041,918
Issuance costs for shares issued under private placement-6,514
Proceeds from exercise of stock options4,675511
Proceeds from borrowings under Credit Facility3,000
Proceeds from issuance of common stock under employee stock purchase plan652748
Net cash provided by / (used in) financing activities47,245-2,255
Net change in cash and cash equivalents-779-104,220
Cash and cash equivalents at beginning of period48,301139,480
Cash and cash equivalents at end of period47,52235,260
Supplemental disclosure of non-cash financing activity
Exchange of common stock for pre-funded warrants29,379
Right-of-use asset obtained in exchange for operating lease liabilities55896

Forward-Looking Statements... (truncated)ancer, including its potential to become a new standard of care in combination with ribociclib in the first-line setting, across multiple regimens and to transform the metastatic breast cancer treatment paradigm; the potential beneficial characteristics, including the safety, tolerability, and efficacy of Olema’s product candidates, including palazestrant and OP-3136, alone and in combination with other agents; the sufficiency of experience of members of our management team; and Olema’s plans to become a fully integrated oncology company. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.

Media and Investor Relations Contact

Courtney O’Konek

Vice President, Corporate Communications

Olema Oncology media@olema.com

Olema Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets Data

(Unaudited)

(In thousands)

Olema Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except for share and per share data)

(1) Research and development expenses for the nine-months ended September 30, 2025 include a $10.0 million milestone payment in connection with the Aurigene Agreement.

(1) and (2) Used to reference to the table below.

(3) The weighted average shares used to compute net loss per share, basic and diluted include the effect from the pre-funded warrants.

Reconciliation of GAAP to Non-GAAP Information

(In thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Olema Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.